(1R)环丙基(2-氟苯基)甲胺盐酸盐 | 1213846-75-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (1R)环丙基(2-氟苯基)甲胺盐酸盐
• 英文名称: (R)-Cyclopropyl(2-fluorophenyl)methanamine hydrochloride
• 英文别名: (R)-cyclopropyl-(2-fluorophenyl)methanamine;hydrochloride
• CAS: 1213846-75-3
• 化学式: C₁₀H₁₂FN*ClH
• 分子量: 201.671
• InChiKey: ZERUEQOFZLOJJX-HNCPQSOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(7-Azaindol-3-yl)-1,3,4-oxadiazol-2(3H)-one 、 (1R)环丙基(2-氟苯基)甲胺盐酸盐 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(R)-cyclopropyl-(2-fluorophenyl)methyl]-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine
  参考文献：
  名称：

  The optimization of aminooxadiazoles as orally active inhibitors of Cdc7

  摘要：

  A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50 = 0.71 mu M measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.055
• 作为产物：
  描述：

  在 盐酸 作用下， 以 甲醇 为溶剂， 生成 (1R)环丙基(2-氟苯基)甲胺盐酸盐
  参考文献：
  名称：

  The optimization of aminooxadiazoles as orally active inhibitors of Cdc7

  摘要：

  A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50 = 0.71 mu M measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.055